STAT+: Wagering on FDA changes, Regenxbio will submit Duchenne gene therapy for approval
Regenxbio plans to submit its Duchenne gene therapy for FDA approval, just a month after it said that regulators wanted to see another trial.
All sources
- STAT News · Center
Prism News is a free news aggregator that breaks every story into Left, Center and Right perspectives — see what each side covers, what they ignore, and how the same event gets framed differently.